Skip to main content

US Venture Partners X LP's Form 4 filing

eFFECTOR Therapeutics, Inc.EFTR · filed Nov 22, 2021

Accession no.
0001062993-21-011394
Filed
Nov 22, 2021, 7:12 PM ET
Trade date
Nov 18-22, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions. Open-market sales total $407.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
US Venture Partners X LPCIK 000144051410% Owner
Usvp X Affiliates LPCIK 000145335910% Owner
Tansey Casey MCIK 000147432210% Owner
Presidio Management Group X LLCCIK 000160274410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 18, 2021Common StockSSaleDisposed−16,226$8.53F1−$138,375.334,549,398Indirect
Nov 18, 2021Common StockSSaleDisposed−519$8.53F1−$4,426.03145,544Indirect
Nov 19, 2021Common StockSSaleDisposed−7,017$8.12F1−$56,985.064,542,381Indirect
Nov 19, 2021Common StockSSaleDisposed−224$8.12F1−$1,818.88145,320Indirect
Nov 22, 2021Common StockSSaleDisposed−25,371$7.86F1−$199,416.064,517,010Indirect
Nov 22, 2021Common StockSSaleDisposed−812$7.86F1−$6,382.32144,508Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $9.12, inclusive for sales on 11/18/21; prices ranging from $8.04 to $8.24, inclusive for sales on 11/19/21; prices ranging from $7.75 to $8.06, inclusive for sales on 11/22/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Referenced by the price of 6 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)